Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rita Nahta

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
ISRN Oncology|December 11, 2012
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerRita Nahta
Breast Cancer (Dove Medical Press)|July 23, 2013
New developments in the treatment of HER2-positive breast cancerRita Nahta
Chemotherapy Research and Practice|July 26, 2012
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistanceRita Nahta
Expert Opinion on Biological Therapy|April 10, 2013
Human epidermal growth factor receptor 2-targeted therapies in breast cancerRita Nahta
Expert Opinion on Biological Therapy|January 20, 2018
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancerElisavet Paplomata, Rita Nahta
Molecular Cancer Research : MCR|June 3, 2008
A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cellsTuba Ozbay, Rita Nahta
Breast Cancer : Basic and Clinical Research|July 28, 2011
Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell LinesTuba Ozbay, Rita Nahta
Current Pharmacogenomics and Personalized Medicine|December 14, 2011
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell LinesAnatasha Crawford, Rita Nahta
Biochemical Pharmacology|December 14, 2020
Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancerRita Nahta, Robert Craig Castellino
Cancer Chemotherapy and Pharmacology|November 8, 2003
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cellsRita Nahta, Francisco J Esteva
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
ISRN Oncology|December 11, 2012
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerRita Nahta
Breast Cancer (Dove Medical Press)|July 23, 2013
New developments in the treatment of HER2-positive breast cancerRita Nahta
Chemotherapy Research and Practice|July 26, 2012
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistanceRita Nahta
Expert Opinion on Biological Therapy|April 10, 2013
Human epidermal growth factor receptor 2-targeted therapies in breast cancerRita Nahta
Expert Opinion on Biological Therapy|January 20, 2018
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancerElisavet Paplomata, Rita Nahta
Molecular Cancer Research : MCR|June 3, 2008
A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cellsTuba Ozbay, Rita Nahta
Breast Cancer : Basic and Clinical Research|July 28, 2011
Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell LinesTuba Ozbay, Rita Nahta
Current Pharmacogenomics and Personalized Medicine|December 14, 2011
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell LinesAnatasha Crawford, Rita Nahta
Biochemical Pharmacology|December 14, 2020
Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancerRita Nahta, Robert Craig Castellino
Cancer Chemotherapy and Pharmacology|November 8, 2003
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cellsRita Nahta, Francisco J Esteva
Pageof 7